Blog

FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

AAFA Offers Free Online Course for Severe Asthma

Severe ASTHMA (Asthma Symptoms, Treatment, Health Management and Activities™) Care for Adults is a FREE self-paced course that helps adults and their caregivers learn how to manage severe asthma. It explains severe and uncontrolled asthma, the impact of severe asthma, asthma management plans and severe asthma treatments.

You’re Invited: Virtual Film Screening and Panel Discussion on “Asthma Alley”

Join the Asthma and Allergy Foundation of America (AAFA), American Lung Association, Allergy & Asthma Network and GroundTruth Films for a virtual film screening of “Asthma Alley,” a short documentary that follows a young teen with asthma and her classmates in the South Bronx, a neighborhood known for extraordinarily high rates of asthma.

GSK, Maker of ADVAIR DISKUS®, Announces Authorized Generic

The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline (GSK) to bring you the latest research news quickly. [PRESS RELEASE] GSK Announces Availability of Authorized Generic ADVAIR DISKUS® (fluticasone propionate/salmeterol inhalation powder) GSK announced today plans to make available an authorized generic (AG) of ADVAIR DISKUS (fluticasone propionate/salmeterol inhalation powder) in all three approved strengths. The authorized generic will be...

AAFA Thanks President Trump for Highlighting America’s Need for Affordable Health Care

On behalf of the more than 60 million Americans with asthma and allergies – many of whom depend on life-saving medications – the Asthma and Allergy Foundation of America (AAFA) thanks President Trump for including pre-existing conditions and affordable health care in his State of the Union address.

AAFA Applauds Senators Grassley and Wyden for Drug Pricing Hearings

On behalf of the more than 60 million Americans with asthma and allergies – many of whom depend on life-saving medications – the Asthma and Allergy Foundation of America (AAFA) applauds Senators Chuck Grassley and Ron Wyden for holding hearings on drug pricing in America. This series of hearings demonstrates the senators’ commitment to exploring the problem of overpriced medications in America.

FDA Approves First Generic ADVAIR DISKUS® for Asthma Treatment

The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Asthma & Allergy-Friendly Valentine’s Day Gifts Show #TealLove

It’s almost Valentine’s Day! It’s a time for romance. A time for schoolchildren to exchange silly cards. And a time for those with asthma and allergies to be extra careful about their triggers. Share the #TealLove this Valentine's Day! What is #TealLove? It is being inclusive of those with asthma and allergies. Your sweetheart won’t appreciate a bottle of perfume or a beautiful bouquet that makes them sneeze and wheeze.   What are common triggers? Many...

Post
×
×
×
×